Clinical trials
EGFR Activating Mutation clinical trials
Below are recruiting egfr activating mutation clinical trials, each written for real people, not researchers. We’re tracking 105 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07392658RecruitingPhase 2
Amivantamab plus chemo for EGFR-mutated lung cancer
This trial tests whether the drug amivantamab combined with a single chemotherapy drug can help people with advanced non-small cell lung cancer that has a specific EGFR gene mutation (exon20 insertion). It is for people who cannot safely receive standard platinum-based chemotherapy.
Roma, Roma (RM)Ages 18–99 - NCT07195695RecruitingPhase 3
Zongertinib after surgery for HER2-mutated lung cancer
This trial tests a new pill, zongertinib, against standard of care for people with early-stage (II–IIIB) non-small cell lung cancer that has a specific HER2 mutation in the tyrosine kinase domain. The goal is to see if zongertinib can prevent the cancer from coming back after complete surgical removal.
Fresno, CaliforniaAges 18 years+ - NCT06970639RecruitingPhase 3
Study comparing new targeted drug plus chemo vs osimertinib for lung cancer with brain tumors
This trial tests a new targeted therapy called furmonertinib combined with chemotherapy against the current standard osimertinib for people with a specific type of non-small cell lung cancer (NSCLC) that has spread to the brain. It aims to find a better treatment option for patients whose cancer cells have a common EGFR mutation.
Guangdong, GuangzhouAges 18 years+ - NCT06706076RecruitingPhase 1/Phase 2
Experimental pill for lung cancer with EGFR or HER2 changes
This study tests an experimental pill that targets cancer cells with certain gene changes (EGFR or HER2). It may help shrink tumors or slow the cancer's growth in people with advanced non-small cell lung cancer.
Phoenix, ArizonaAges 18 years+ - NCT06192849RecruitingPhase 2
Furmonertinib after surgery for EGFR 20 insertion lung cancer
This trial tests a targeted pill (furmonertinib) to prevent your lung cancer from coming back after surgery. It is for people with a certain genetic change in their tumor (EGFR exon 20 insertion) and stage IB, II, or IIIA disease.
Chengdu, SichuanAges 18 years+ - NCT06226857RecruitingPhase 3
Anti-EGFR for left-sided, RAS wild-type metastatic colorectal cancer
This trial tests whether anti-EGFR therapy works better for people with left-sided colorectal cancer that has spread, whose tumors do not have certain gene mutations (RAS wild-type). It is for those who have not yet had treatment for metastatic disease.
MoscowAges 18–99 - NCT06514027RecruitingPhase 2
Study of BEBT-109 for lung cancer with EGFR exon 20 insertion mutation
This trial tests a new drug called BEBT-109 for people with a specific type of non-small cell lung cancer that has an EGFR exon 20 insertion mutation. It's for those who haven't had prior treatment for advanced or metastatic lung cancer, and it aims to see if the drug can help shrink or control the cancer.
Guangzhou, GuangdongAges 18 years+ - NCT06043817RecruitingPhase 1/Phase 2
Study of STX-721 for advanced lung cancer with EGFR or HER2 changes
This trial tests a new drug, STX-721, for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR or HER2 exon 20 insertion). The study aims to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT07462377RecruitingPhase 1
Testing EPI-326 for EGFR-mutant lung and head & neck cancers
This trial tests a new drug, EPI-326, in people with advanced lung or head & neck cancers that have certain EGFR changes. The goal is to see if it is safe and may help shrink the cancer.
Los Angeles, CaliforniaAges 18 years+
Hear when a new EGFR Activating Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for egfr activating mutation?
- Yes. Clin2 currently lists 105 recruiting egfr activating mutation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a egfr activating mutation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a egfr activating mutation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.